Skip to main content

Table 1 Clinical characteristics of patients.

From: Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma

Variables

HCC Cohort

(N = 47)

Nontumoral HCC cohort

(N = 44)

Tumor HCC cohort

(N = 43)

Control liver cohort (metastatic liver tumors, N = 8)

Age

66.5 ± 7.8

66.4 ± 7.9

66.5 ± 7.9

60.0 ± 13.5

Gender

    

   Male

35 (74.4%)

32 (72.7%)

32 (74.4%)

4 (50.0%)

   Female

12 (25.5%)

12 (27.3%)

11 (25.6%)

4 (50.0%)

Viral infection status

    

   HBV infection

-

-

-

-

   HCV infection

+

+

+

-

Liver resection procedure

    

   Lobular/extended lobular

5

5

5

N/A

   Segmental/partial

42

39

38

 

Platelet count (104/μl)

12.9 ± 4.3

13.0 ± 4.2

12.8 ± 4.2

19.3+3.6*

Alanine aminotransferase (IU/l)

51.0 ± 31.7

51.0 ± 32.0

51.7 ± 33.1

19.7+7.7*

Total bilirubin (mg/dl)

0.80 ± 0.34

0.76 ± 0.30

0.80 ± 0.35

0.85+0.37

Prothrombin time (%)

78.3 ± 13.1

78.3 ± 12.9

78.1 ± 13.3

91.1+14.5

Indocyanine green (%)

18.4 ± 8.3

18.5 ± 8.3

18.3 ± 8.4

11.0+5.3

α-Fetoprotein (ng/ml)

319 ± 924

339 ± 952

345 ± 962

N/A

Tumor diameter (cm)

2.90 ± 1.30

2.97 ± 1.35

2.95 ± 1.37

N/A

Number of tumors

1.30 ± 0.50

1.32 ± 0.52

1.30 ± 0.51

N/A

Portal vein invasion

    

   Present

5 (10.6%)

5 (11.4%)

5 (11.6%)

N/A

   Absent

42 (89.4%)

39 (88.6%)

38 (88.4%)

N/A

Tumor stage

    

   I

9 (19.1%)

9 (20.5%)

8 (18.6%)

N/A

   II

25 (53.2%)

23 (52.3%)

24 (55.8%)

N/A

   III

12 (25.5%)

11 (25.0%)

10 (23.3%)

N/A

   IV

1 (2.1%)

1 (2.3%)

1 (2.3%)

N/A

Tumor differentiation

    

   Well differentiated

8 (17.0%)

8 (18.2%)

6 (14.0%)

N/A

   Moderately differentiated

31 (66.0%)

28 (63.6%)

29 (67.4%)

N/A

   Poorly differentiated

8 (17.0%)

8 (18.2%)

8 (18.6%)

N/A

Fibrosis score

    

   F0

0 (0%)

0 (0%)

0 (0%)

8 (100%)*

   F1

3 (6.4%)

3 (6.8%)

3 (7.0%)

0 (0%)

   F2

6 (12.8%)

5 (11.4%)

6 (14.0%)

0 (0%)

   F3

14 (29.8%)

14 (31.8%)

12 (27.9%)

0 (0%)

   F4

24 (51.1%)

22 (50.0%)

22 (51.2%)

0 (0%)

  1. Data shown are mean ± standard deviation. N/A, data is not available. Asterisk(*) denotes statistical difference from other groups (ANOVA, p < 0.05).
Back to article page

Molecular Cancer

ISSN: 1476-4598